Book Online or Call 1-855-SAUSALITO
Sign In \| Register \| About Sausalito \| Contact Us
Sausalito, CA September 01, 2020 1:41pm 7-Day Forecast \| Traffic

- Apartments

Search Hotels in Sausalito
CHECK-IN:
CHECK-OUT:
ROOMS:

Find A Business
or Browse Listings

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Pfizer (NY:PFE)

27.61 +0.56 (+2.07%)

Official Closing Price Updated: 7:00 PM EST, Feb 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Looking for the most active stocks in the S&P500 index on Monday? ↗

January 05, 2026

Via Chartmill

This Flying-Under-the-Radar Pharma Stock Pays Nearly 7% (While Everyone's Sleeping) ↗

January 05, 2026

Investors seem to be underestimating this company's foreseeable future.

Via The Motley Fool

These 3 Stocks Trade at Discounts the Market Won’t Ignore Forever ↗

January 05, 2026

Via MarketBeat

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

January 05, 2026

From Pfizer Inc.

Via Business Wire

Is It Time to Dump Your Shares of Eli Lilly? ↗

January 05, 2026

Eli Lilly has the lead in the GLP-1 race, but Novo Nordisk just changed the game.

Via The Motley Fool

Better Dividend Stock: Ford vs. Pfizer ↗

January 05, 2026

Both Ford and Pfizer have very attractive dividend yields.

Via The Motley Fool

26 Top Dividend Stocks to Buy and Hold in 2026 ↗

January 05, 2026

Another year, another long list of great dividend stocks.

Via The Motley Fool

Topics Intellectual Property

3 Stocks Under $50 with Questionable Fundamentals

January 04, 2026

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to...

Via StockStory

How Safe Is Pfizer's Dividend As 2026 Begins? ↗

January 03, 2026

Income investors probably don't need to worry about a dividend cut from Pfizer in the new year.

Via The Motley Fool

2 Predictions for Pfizer in 2026 ↗

January 02, 2026

The company's prospects are stronger than its stock-market performance in 2025 suggests.

Via The Motley Fool

Topics Intellectual Property

Momentum in Healthcare and Banking to Persist in 2026 as AstraZeneca and Citigroup Lead the Charge

January 02, 2026

As the global markets open for the first week of 2026, a clear narrative has emerged: the "recovery plays" of 2025 have officially transformed into the "expansion leaders" of the new year. Following a...

Via MarketMinute

Topics Artificial Intelligence Economy Initial Public Offering

The 2026 Pharma Reset: How Industry Giants Are Navigating a New Era of Federal Price Controls

January 02, 2026

Yesterday marked the official commencement of the first-ever "Maximum Fair Prices" (MFPs) for ten of the most widely used drugs in the Medicare program, a direct result of the Inflation Reduction Act’s...

Via MarketMinute

Topics Economy Intellectual Property World Trade

The RNAi Powerhouse: A Deep Dive into Alnylam Pharmaceuticals’ Path to the S&P 500

January 02, 2026

As the calendar turns to 2026, Alnylam Pharmaceuticals (Nasdaq: ALNY) stands at the threshold of a new era. Once a speculative pioneer in the arcane world of RNA interference (RNAi), the...

Via PredictStreet

Topics Economy Intellectual Property Stocks

The Great Rebound: US M&A Poised for Record-Breaking 2026 as Interest Rates Stabilize

January 01, 2026

As the calendar turns to January 1, 2026, the United States financial markets are witnessing a dramatic transformation in the landscape of corporate dealmaking. After a multi-year "deal desert"...

Via MarketMinute

Topics Artificial Intelligence Economy

Pfizer’s Dividend Trap or Deep Value? Analyzing the Pharma Giant as Shares Languish Below $30

January 01, 2026

As the calendar turns to January 1, 2026, Pfizer Inc. (NYSE: PFE) finds itself in a position that would have been unthinkable during the height of the pandemic. Once the darling of the pharmaceutical...

Via MarketMinute

Topics Intellectual Property

Economic Revolution or Looming Recession? Trump’s ‘A++’ Claims Clash with Wall Street’s Cautious 2026 Outlook

January 01, 2026

As the sun rises on January 1, 2026, the United States finds itself at a historical crossroads, caught between the triumphant rhetoric of an "Economic Revolution" and the sobering data of a cooling...

Via MarketMinute

Topics Artificial Intelligence Economy Government

Should You Buy Pfizer While It's Under $30? ↗

January 01, 2026

It might not pay off immediately, but it could, eventually.

Via The Motley Fool

Topics Government Intellectual Property World Trade

Investing $122,100 in These 3 High-Yield Dividend Stocks Could Make You $10,000 in Reliable Passive Income in 2026 ↗

January 01, 2026

The money could flow in with these great dividend stocks.

Via The Motley Fool

1 Momentum Stock to Target This Week and 2 That Underwhelm

December 31, 2025

The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant...

Via StockStory

Where Will Pfizer Be in 5 Years? ↗

December 31, 2025

Pfizer's stock is down roughly 60% from its late 2021 highs, but the drug giant is working to innovate its way back into the big leagues.

Via The Motley Fool

Topics Intellectual Property

The Metabolic Squeeze: Big Pharma’s 2025 Defined by $1 Trillion Valuations and Regulatory Reckonings

December 31, 2025

As 2025 draws to a close, the pharmaceutical industry stands at a historic crossroads. The year was defined by a widening chasm between the "metabolic haves"—those profiting from the global obesity...

Via MarketMinute

Topics Economy Intellectual Property Law Enforcement

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Why Wall Street Gave Up on Pfizer—and Why That May Be a Mistake ↗

December 31, 2025

Via MarketBeat

2 Unstoppable Dividend Stocks to Double Up on Right Now ↗

December 31, 2025

It's always a great time to buy quality dividend stocks.

Via The Motley Fool

Pfizer Leads New Wave Of 2026 US Drug Price Hikes Despite Trump’s Drug Cost Crackdown: Report ↗

December 31, 2025

Drugmakers are outlining 2026 list price changes, with most adjustments typically announced in January.

Via Stocktwits

Topics Economy Government

Tuesday's session: most active stock in the S&P500 index ↗

December 30, 2025

Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Tuesday and uncover the stocks that are leading the way in terms of trading volume and market...

Via Chartmill

The Trillion-Dollar Shuffle: How Year-End Institutional Rebalancing is Fueling Late-December Volatility

December 30, 2025

As the final trading days of 2025 unfold, the financial markets are witnessing a phenomenon that analysts have dubbed the "Great Rebalancing." While the S&P 500 is poised to finish the year with...

Via MarketMinute

Topics Artificial Intelligence Bonds ETFs

The Great Consolidation: Why 2026 is Set to Become the Year of the Mega-Deal

December 30, 2025

As 2025 draws to a close, the global financial landscape is bracing for what analysts are calling an "Innovation Supercycle" in the mergers and acquisitions (M&A) market. With interest rates finally...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Hunterbrook Capital Bets Big on Achieve Life Sciences: Why a 'Toxic Tree' Could Disrupt the Multi-Billion Dollar Smoking Cessation Market

December 30, 2025

In a move that has sent ripples through the biotech sector on the final trading days of the year, Hunterbrook Capital announced a significant bullish position in Achieve Life Sciences (NASDAQ:ACHV)...

Via MarketMinute

Topics Product Recall

Achieve Life Sciences’ Smoking Treatment Likely To Be Approved By FDA, Says Hunterbrook ↗

December 30, 2025

The FDA is expected to rule on Achieve Life Sciences’ application seeking approval for the drug by June 20, 2026.

Via Stocktwits

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Search Hotels in Sausalito

Find A Business

or Browse Listings

Pfizer (NY:PFE)

All News about Pfizer